摘要
目的探讨血清骨硬化蛋白(Sclerostin)、内皮细胞特异性分子1(Endocan)与2型糖尿病(T2DM)亚临床动脉粥样硬化(SAS)的关系。方法选取2019年2月—2021年3月郴州市第一人民医院收治的117例T2DM患者为研究对象,统计T2DM患者SAS发生情况;分析血清Sclerostin、Endocan与颈动脉内膜中膜厚度(CIMT)的相关性;分析T2DM患者发生SAS的影响因素;分析血清Sclerostin、Endocan预测T2DM患者发生SAS的价值。结果117例T2DM患者中有68例(58.12%)出现SAS。单因素分析结果显示:T2DM患者SAS的发生与年龄、T2DM病程、合并高血压、空腹血糖(FPG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDLC)、纤维蛋白原、CIMT、Sclerostin、Endocan有关(P<0.05)。多因素Logistic回归分析结果显示:年龄、LDLC、CIMT、FPG、Sclerostin、Endocan均是T2DM患者发生SAS的影响因素(P<0.05)。Pearson相关性分析结果显示:Sclerostin、Endocan与CIMT均呈正相关(P<0.05)。受试者工作特征(ROC)曲线分析结果显示:血清Sclerostin、Endocan及二者联合预测T2DM患者发生SAS的曲线下面积(AUC)分别为0.771(95%CI:0.616~0.926)、0.712(95%CI:0.493~0.929)、0.827(95%CI:0.657~0.988)。结论T2DM患者并发SAS的风险较高,血清Sclerostin、Endocan与T2DM患者发生SAS有关,二者联合可以预测T2DM患者SAS的发生。
Aim To explore the relationship between serum Sclerostin, Endocan and type 2 diabetes mellitus(T2DM) subclinical atherosclerosis(SAS). Methods 117 cases of T2DM patients who were admitted to Chenzhou First People’s Hospital from February 2019 to March 2021 were selected as the research objects, and the occurrence of SAS in T2DM patients was counted. The correlation between serum Sclerostin, Endocan and common carotid artery intima-media thickness(CIMT) were analyzed. The influencing factors of SAS in T2DM patients were analyzed. The value of serum Sclerostin and Endocan in predicting the occurrence of SAS in T2DM patients was analyzed. Results 68 cases(58.12%) developed SAS among the 117 cases of T2DM patients. The results of univariate analysis showed that the occurrence of SAS in T2DM patients was related to age, course of T2DM, complicated with hypertension, fasting plasma glucose(FPG), total cholesterol(TC), low density lipoprotein cholesterol(LDLC), fibrinogen, CIMT, Sclerostin and Endocan(P<0.05). The results of multivariate Logistic regression analysis showed that age, LDLC, CIMT, FPG, Sclerostin and Endocan were all influencing factors for the occurrence of SAS in T2DM patients(P<0.05). The results of Pearson correlation analysis showed that Sclerostin and Endocan were positively correlated with CIMT(P<0.05). Receiver operating characteristic(ROC) curve analysis showed that the area under the curve(AUC) of serum Sclerostin, Endocan and their combination in predicting the occurrence of SAS in T2DM patients were 0.771(95%CI: 0.616~0.926), 0.712(95%CI: 0.493~0.929) and 0.827(95%CI: 0.657~0.988), respectively. Conclusions T2DM patients have a higher risk of developing SAS. Serum Sclerostin and Endocan are related to the occurrence of SAS in T2DM patients. The combination of the two has a high efficiency in predicting the occurrence of SAS in T2DM patients.
作者
谭艳飞
谭艳美
梅琅
TAN Yanfei;TAN Yanmei;MEI Lang(Department of Endocrine,Chenzhou First Peoples Hospital&the First Affiliated Hospital of Xiangnan University,Chenzhou,Hunan 423000,China;Basic Medical College of Xiangnan University,Chenzhou,Hunan 423000,China)
出处
《中国动脉硬化杂志》
CAS
2022年第5期410-415,共6页
Chinese Journal of Arteriosclerosis
基金
湖南省自然科学基金立项项目(2019JJ40012)。
